Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

US And Canada

Vera wraps up $80m series C
Yale-linked Vera has rebranded from Trucode Gene Repair and will use the money to move towards clinical trials.
NexImmune elects to launch initial public offering
Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.
Bolt Biotherapeutics charges to IPO stage
Novo and Pfizer are among the investors set to exit the Stanford spinout, which has set a $100m target for its initial public offering.
Vor Biopharma goes for $150m in IPO
Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.
Verve Therapeutics turns to $94m series B
Novo and GV participated in a round that lifted the Harvard, Broad Institute and Penn-linked heart disease drug developer's overall funding to more than $215m.
Karslake slides into UChicago’s Polsky Center
Christine Karslake is set to lead UChicago’s Polsky Science Ventures unit and will be tasked with setting up a deep tech-focused accelerator.
US universities launch Academic Accelerator
Indiana University is among four US institutions selected by the US Department of Defense's open national security innovation programme for a new accelerator targeting applied research spinouts.
AltPep unpacks $23.1m round
University of Washington spinout AltPep will use the money to advance work on its lead asset that targets Alzheimer’s disease.

Other News

Pignato pulls out of Allied Minds
Allied Minds will henceforth operate without a chief executive after Joseph Pignato announced his decision to resign.
BlueSphere Bio brings in $45.6m
Pitt spinout BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target size.
Biohaven brings Kleo into the fold
Existing shareholder Biohaven has agreed to purchase the remaining stake in Kleo Pharmaceuticals, a Yale spinout it first backed in 2016.
Johnson & Johnson turns Paige to $100m
Johnson & Johnson Innovation – JJDC has co-led the computational pathology technology provider's series C round to take its total funding to $195m.
Atalanta attains series A
Atalanta Therapeutics has launched out of UMass with $110m in combined series A and partnership funding to develop therapies for neurodegenerative diseases.
Sana to seek $150m in IPO
Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.

Editor's Picks

Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Editorial: For the good of investors
As MedWhat scores an initial win in its courtroom battle with Stanford, finds itself in the middle of allegations that its licensing deal with Sloan Kettering was improper.
Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Big deal: QuantumScape fuels up on VW cash
VW will invest $100m in QuantumScape and form a joint venture with the Stanford spinout to develop batteries for long-range electric vehicles.
test reg